

Jared Probst, M.D.
CCT Research
1910 S Stapley Drive, Suite 120
Mesa, AZ 85204

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 803-7149 (cell)
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

South Ogden Family Practice/Ogden Clinic/CCT Research
5740 Crestwood Drive
South Ogden, UT 84405

Olympus Family Medicine/ CCT Research
4624 Holladay Blvd E
Salt Lake City, UT 84117

EDUCATION:

1996 MD
University of Utah School of Medicine, Salt Lake City, Utah

1992 BS Sociology
Utah State University, Logan, Utah

LICENSURE:

Utah - Physician - License Number: 373445-1205
Utah - Physician CS - License Number: 373445-8905

RESIDENCY:

1996-1999 Family Practice
Medical College of Wisconsin, Milwaukee, Wisconsin

CERTIFICATION:

American Board of Family Medicine – Certified

PROFESSIONAL EXPERIENCE:

Principal Investigator, 2020 – present
CCT Research, Utah

Principal Investigator, 2016 – 2020
Accelerated Enrollment Solutions (formerly Synexus Clinical Research), Holladay, Utah

Family Practice Physician, 1999 – Present
Olympus Family Medicine, Holladay, Utah

Emergency Physician, 1998 – 1999
St. Nicholas Hospital, Sheboygan, Wisconsin

Urgent Care Physician, 1997 – 1999
St. Mary's Clinic, Milwaukee, Wisconsin

Volunteer Physician, 1997 – 1999
Isaac Coggs Homeless Clinic, Milwaukee, Wisconsin

INVESTIGATOR EXPERIENCE:

COVID-19 Diagnostic Studies • COVID-19 Treatment Studies • Influenza • Type 2 Diabetes

ADDITIONAL INTEREST:

Acne and Atopic Dermatitis • Allergy • Angina • Ankle Sprain • Anxiety • Arrhythmia • Arthritis
Asthma • Atrial Fibrillation • Cardiovascular Device • Congestive Heart Failure
Coronary Artery Disease • Depression • Type 1 Diabetes • Diabetic Neuropathy
Diabetic Retinopathy • Diabetic Nephropathy • GERD • Gout • Hyperlipidemia • Hypertension
Irritable Bowel Syndrome • Lateral Epicondylitis (tennis elbow) • Metabolic Syndrome • Obesity
Osteoporosis • Otitis Media • Overactive Bladder • Pain Management • Parkinson's Disease
Pediatric Diabetes • Pediatric Hypercholesterolemia • Pediatric Hypertension
Rheumatoid Arthritis • Sexual Dysfunction • Sexually Transmitted Disease • Smoking Cessation
Tinea Pedis (Athlete's Foot) • Thyroid Disorders • Ulcerative Colitis • Women's Health Studies
Vaccines (COVID and other) • Oncology • Other Internist Indications

CLINICAL TRIAL EXPERIENCE:

COVID-19

A Phase II, Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of XXX in Adults With Mild COVID-19 Symptoms

CLINICAL TRIAL EXPERIENCE (*continued*):

A Diagnostic Clinical Performance Validation of XXX , SARS-CoV-2 (COVID-19) Rapid Antigen Detection Assay, in the Point of Care Setting

A Phase II, Randomized, Double blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-Coronavirus Response of Suppression of XXX in Out-patient Adults with SARS-CoV-2 (The XXX Study)

An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of XXX in Adult Patients with Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting

A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of XXX in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients with Mild-to-Moderate COVID-19

Clinical Evaluation of the XXX COVID-19 Ag AnTigen (Ag) Assay in Symptomatic Subjects (CATSS)

Influenza

A Multicenter Study Conducted to Evaluate the Performance of the XXX Flu A&B Assay at Point of Care Testing Sites

Type 2 Diabetes

A 52 Week Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety Of XXX Compared To XXX Or Placebo Added To XXX In Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Monotherapy

A 26 Week Randomized, Double-Blind, Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety Of XXX Compared To XXX, And Placebo In Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control On Dipeptidyl Peptidase 4 Inhibiter (DPP4I) With Or Without Metformin

A 56 Week, Multicenter, Double-Blind, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of XXX Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise

Vaccines

A Phase III, Randomized, Active-controlled, Observer-blinded Trial to Assess the Safety, Tolerability, and Immunogenicity of XXX in Healthy Participants ≥ 10 to < 26 Years of Age